254 related articles for article (PubMed ID: 23275803)
1. Frontier of therapeutic antibody discovery: The challenges and how to face them.
Lu ZJ; Deng SJ; Huang DG; He Y; Lei M; Zhou L; Jin P
World J Biol Chem; 2012 Dec; 3(12):187-96. PubMed ID: 23275803
[TBL] [Abstract][Full Text] [Related]
2.
André AS; Moutinho I; Dias JNR; Aires-da-Silva F
Front Microbiol; 2022; 13():962124. PubMed ID: 36225354
[TBL] [Abstract][Full Text] [Related]
3. Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics.
Martin KP; Grimaldi C; Grempler R; Hansel S; Kumar S
MAbs; 2023; 15(1):2191301. PubMed ID: 36998195
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Antibody Engineering and Selection Strategies.
Ministro J; Manuel AM; Goncalves J
Adv Biochem Eng Biotechnol; 2020; 171():55-86. PubMed ID: 31776591
[TBL] [Abstract][Full Text] [Related]
5. Phage display-derived human antibodies in clinical development and therapy.
Frenzel A; Schirrmann T; Hust M
MAbs; 2016 Oct; 8(7):1177-1194. PubMed ID: 27416017
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.
Karle A; Spindeldreher S; Kolbinger F
MAbs; 2016; 8(3):536-50. PubMed ID: 26817498
[TBL] [Abstract][Full Text] [Related]
7. Human monoclonal antibodies from transgenic mice.
Lonberg N
Handb Exp Pharmacol; 2008; 181(181):69-97. PubMed ID: 18071942
[TBL] [Abstract][Full Text] [Related]
8. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries.
Dyson MR; Masters E; Pazeraitis D; Perera RL; Syrjanen JL; Surade S; Thorsteinson N; Parthiban K; Jones PC; Sattar M; Wozniak-Knopp G; Rueker F; Leah R; McCafferty J
MAbs; 2020; 12(1):1829335. PubMed ID: 33103593
[TBL] [Abstract][Full Text] [Related]
9. Rapid optimization and prototyping for therapeutic antibody-like molecules.
Xu L; Kohli N; Rennard R; Jiao Y; Razlog M; Zhang K; Baum J; Johnson B; Tang J; Schoeberl B; Fitzgerald J; Nielsen U; Lugovskoy AA
MAbs; 2013; 5(2):237-54. PubMed ID: 23392215
[TBL] [Abstract][Full Text] [Related]
10. Antibody discovery: sourcing of monoclonal antibody variable domains.
Strohl WR
Curr Drug Discov Technol; 2014 Mar; 11(1):3-19. PubMed ID: 24168292
[TBL] [Abstract][Full Text] [Related]
11. Dual display: phage selection driven by co-engagement of two targets by two different antibody fragments.
Fagète S; Botas-Perez L; Rossito-Borlat I; Adea K; Gueneau F; Ravn U; Rousseau F; Kosco-Vilbois M; Fischer N; Hartley O
Protein Eng Des Sel; 2017 Sep; 30(9):575-582. PubMed ID: 28444391
[TBL] [Abstract][Full Text] [Related]
12. BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning.
Prihoda D; Maamary J; Waight A; Juan V; Fayadat-Dilman L; Svozil D; Bitton DA
MAbs; 2022; 14(1):2020203. PubMed ID: 35133949
[TBL] [Abstract][Full Text] [Related]
13. Selection of Recombinant Human Antibodies.
Tomszak F; Weber S; Zantow J; Schirrmann T; Hust M; Frenzel A
Adv Exp Med Biol; 2016; 917():23-54. PubMed ID: 27236551
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics.
Ahmed L; Gupta P; Martin KP; Scheer JM; Nixon AE; Kumar S
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34504010
[TBL] [Abstract][Full Text] [Related]
15. Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.
Harth S; Ten Haaf A; Loew C; Frisch C; Knappik A
MAbs; 2019 Jan; 11(1):178-190. PubMed ID: 30516449
[TBL] [Abstract][Full Text] [Related]
16. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.
Almagro JC; Daniels-Wells TR; Perez-Tapia SM; Penichet ML
Front Immunol; 2017; 8():1751. PubMed ID: 29379493
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Antibodies by Phage Display.
Shim H
Curr Pharm Des; 2016; 22(43):6538-6559. PubMed ID: 27669967
[TBL] [Abstract][Full Text] [Related]
18. Engineered antibodies take center stage.
Huston JS; George AJ
Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
[TBL] [Abstract][Full Text] [Related]
19. Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies.
Johnson DE
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469350
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?
Dimitrov DS; Marks JD
Methods Mol Biol; 2009; 525():1-27, xiii. PubMed ID: 19252861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
